Jones J - Search Results

1

Transcript specific regulation of expression influences susceptibility to multiple sclerosis.

Ban M, Liao W, Baker A, Compston A, Thorpe J, Molyneux P, Fraser M, Khadake J, Jones J, Coles A, Sawcer S. Ban M, et al. Among authors: jones j. Eur J Hum Genet. 2020 Jun;28(6):826-834. doi: 10.1038/s41431-019-0569-0. Epub 2020 Jan 13. Eur J Hum Genet. 2020. PMID: 31932686 Free PMC article.

2

Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis.

Davies JL, Thompson S, Kaur-Sandhu H, Sawcer S, Coles A, Ban M, Jones J. Davies JL, et al. Among authors: jones j. PLoS One. 2016 Jul 20;11(7):e0158327. doi: 10.1371/journal.pone.0158327. eCollection 2016. PLoS One. 2016. PMID: 27438997 Free PMC article.

3

Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells.

Smets I, Fiddes B, Garcia-Perez JE, He D, Mallants K, Liao W, Dooley J, Wang G, Humblet-Baron S, Dubois B, Compston A, Jones J, Coles A, Liston A, Ban M, Goris A, Sawcer S. Smets I, et al. Among authors: jones j. Brain. 2018 Mar 1;141(3):786-796. doi: 10.1093/brain/awx372. Brain. 2018. PMID: 29361022 Free PMC article.

4

Campath-1H treatment of multiple sclerosis.

Jones JL, Coles AJ. Jones JL, et al. Neurodegener Dis. 2008;5(1):27-31. doi: 10.1159/000109935. Neurodegener Dis. 2008. PMID: 18075272 Review.

5

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ. Jones JL, et al. J Clin Invest. 2009 Jul;119(7):2052-61. doi: 10.1172/JCI37878. Epub 2009 Jun 22. J Clin Invest. 2009. PMID: 19546505 Free PMC article.

6

New treatment strategies in multiple sclerosis.

Jones JL, Coles AJ. Jones JL, et al. Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Exp Neurol. 2010. PMID: 20547155 Review.

7

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

Azzopardi L, Thompson SA, Harding KE, Cossburn M, Robertson N, Compston A, Coles AJ, Jones JL. Azzopardi L, et al. Among authors: jones jl. J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):795-8. doi: 10.1136/jnnp-2013-307042. Epub 2013 Dec 24. J Neurol Neurosurg Psychiatry. 2014. PMID: 24368840

8

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.

Kousin-Ezewu O, Azzopardi L, Parker RA, Tuohy O, Compston A, Coles A, Jones J. Kousin-Ezewu O, et al. Among authors: jones j. Neurology. 2014 Jun 17;82(24):2158-64. doi: 10.1212/WNL.0000000000000520. Epub 2014 May 16. Neurology. 2014. PMID: 24838790 Free PMC article. Clinical Trial.

9

Spotlight on alemtuzumab.

Jones JL, Coles AJ. Jones JL, et al. Int MS J. 2009 Sep;16(3):77-81. Int MS J. 2009. PMID: 19878629 Review.

10

First use of alemtuzumab in Balo's concentric sclerosis: a case report.

Brown JW, Coles AJ, Jones JL. Brown JW, et al. Among authors: jones jl. Mult Scler. 2013 Oct;19(12):1673-5. doi: 10.1177/1352458513498129. Epub 2013 Jul 25. Mult Scler. 2013. PMID: 23886830

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,367 results

Search Page